FASENRA should not be used to treat acute asthma exacerbations.
Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.
Abrupt discontinuation of corticosteroids after initiation of FASENRA therapy is not recommended. Reduction in corticosteroid doses, if appropriate, should be gradual and performed under the supervision of a physician.
Hypersensitivity reactions: Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, urticaria papular, rash) have occurred following administration of FASENRA. These reactions may occur within hours of administration, but in some instances have a delayed onset (i.e., days).
In the event of a hypersensitivity reaction, FASENRA should be discontinued.
Parasitic (helminth) infection: Eosinophils may be involved in the immunological response to some helminth infections. Patients with known helminth infections were excluded from participation in clinical trials. It is unknown if FASENRA may influence a patient's response against helminth infections.
Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving treatment with FASENRA and do not respond to anti-helminth treatment, discontinue treatment with FASENRA until infection resolves.
Effects on ability to drive and use machines: FASENRA has no or negligible influence on the ability to drive and use machines.